Drugs / Rongliflozin
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05374343 | May 2022 → Aug 2023 | type 2 diabetes mellitus | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05427682 | Apr 2022 → Nov 2023 | type 2 diabetes mellitus | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05497674 | Feb → Jul 2022 | type 2 diabetes mellitus | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT05109078 | Dec 2021 | — | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rongliflozin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05109078 ↗ |
| Known as | [14C]- Rongliflozin | “Drug: [14C]- Rongliflozin” NCT05109078 ↗ |
| Modality | Small molecule | — CHEMBL5314927 ↗ |
| Route | Oral | “Patients will receive single dose of orally \[14C\]- Rongliflozin on Day 1” NCT05109078 ↗ |